Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

New Developments in Inhaled Antibiotics for the Treatment of Pseudomonas aeruginosa

Author(s): Thomas Hofmann

Volume 18, Issue 5, 2012

Page: [683 - 695] Pages: 13

DOI: 10.2174/138161212799315975

Price: $65

Abstract

The field of inhaled antibiotics that target Pseudomonas aeruginosa infections has made substantial contributions to the health, disease management, and life expectancies of individuals with cystic fibrosis (CF) over the last three decades [1-3]. This paper reviews some of the recent clinical developments in the field of inhaled antibiotics for CF and briefly describes formulations and ongoing developments for US and/or European regulatory approvals. Lung delivery technologies, in regards to inhaled antibiotics for CF, are also reviewed

Keywords: Inhaled antibiotics, Pseudomonas aeruginosa, cystic fibrosis, aerosol, lung delivery, pneumonia, aerosolized application, tobramycin, drug delivery, nebulizer


Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy
?>